Actelion Grows Its PAH Franchise With Uptravi Approval
Executive Summary
Broad label for oral product could help Actelion weather the loss of Tracleer to generic competition.
You may also be interested in...
Actelion’s Opsumit Ramps Up As Tracleer Patent Loss Gets Closer
The Swiss biotech’s top-selling product Tracleer still accounts for 75% of its sales but Actelion has a strategy that includes launching new PAH therapies and developing a specialty pharma pipeline to cope with the upcoming loss of patent protection.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.